<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250214051130&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250214051130&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 14 Feb 2025 10:11:31 +0000</lastbuilddate>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Focus on aortic stenosis prevention and mitral regurgitation diagnosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39947236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 14;46(7):595-597. doi: 10.1093/eurheartj/ehaf015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39947236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39947236</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf015>10.1093/eurheartj/ehaf015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39947236</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on aortic stenosis prevention and mitral regurgitation diagnosis</dc:title>
<dc:identifier>pmid:39947236</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf015</dc:identifier>
</item>
<item>
<title>Resistance to Striga parasitism through reduction of strigolactone exudation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39947180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Parasitism with Striga poses a major threat to global food production. Striga germination and growth rely on strigolactones (SLs) exuded by crop roots under phosphate (Pi)-deficient conditions, although the mechanism of this host-parasite interaction remains elusive. In this study, transcriptomic and functional analyses of sorghum treated with Pi deficiency or the SL GR24^(5DS) identify two ABC transporter G (ABCG) transporters of SL, Sorghum biocolor strigolactones transporter 1 (SbSLT1) and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 4:S0092-8674(25)00086-8. doi: 10.1016/j.cell.2025.01.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Parasitism with Striga poses a major threat to global food production. Striga germination and growth rely on strigolactones (SLs) exuded by crop roots under phosphate (Pi)-deficient conditions, although the mechanism of this host-parasite interaction remains elusive. In this study, transcriptomic and functional analyses of sorghum treated with Pi deficiency or the SL GR24<sup>5DS</sup> identify two ABC transporter G (ABCG) transporters of SL, Sorghum biocolor strigolactones transporter 1 (SbSLT1) and SbSLT2. Using AlphaFold2 and amino acid conversion mutants, we identify highly conserved amino acids in SL transport channels essential for transport function. Sorghum lines with single or double knockouts of these transporters exhibit significantly reduced SL secretion from roots, leading to decreased Striga germination and parasitism in field experiments and consequently reducing the grain loss under Striga infestation. This study thus describes the mechanism of SL exudation in monocots and defines conserved residues essential for SL transporter function, offering a potential strategy for enhancing crop resistance to Striga parasitism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39947180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39947180</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.022>10.1016/j.cell.2025.01.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39947180</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jiayang Shi</dc:creator>
<dc:creator>Cuo Mei</dc:creator>
<dc:creator>Fengyong Ge</dc:creator>
<dc:creator>Qingliang Hu</dc:creator>
<dc:creator>Xinwei Ban</dc:creator>
<dc:creator>Ran Xia</dc:creator>
<dc:creator>Peiyong Xin</dc:creator>
<dc:creator>Shujing Cheng</dc:creator>
<dc:creator>Gaohua Zhang</dc:creator>
<dc:creator>Jiawei Nie</dc:creator>
<dc:creator>Shiqi Zhang</dc:creator>
<dc:creator>Xiaowei Ma</dc:creator>
<dc:creator>Yi Wang</dc:creator>
<dc:creator>Jinfang Chu</dc:creator>
<dc:creator>Yuhang Chen</dc:creator>
<dc:creator>Bing Wang</dc:creator>
<dc:creator>Weihua Wu</dc:creator>
<dc:creator>Jiayang Li</dc:creator>
<dc:creator>Qi Xie</dc:creator>
<dc:creator>Feifei Yu</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Resistance to Striga parasitism through reduction of strigolactone exudation</dc:title>
<dc:identifier>pmid:39947180</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.022</dc:identifier>
</item>
<item>
<title>ArfGAP2 promotes STING proton channel activity, cytokine transit, and autoinflammation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39947179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Stimulator of interferon genes (STING) transmits signals downstream of the cytosolic DNA sensor cyclic guanosine monophosphate-AMP synthase (cGAS), leading to transcriptional upregulation of cytokines. However, components of the STING signaling pathway, such as IRF3 and IFNAR1, are not essential for autoinflammatory disease in STING gain-of-function (STING-associated vasculopathy with onset in infancy [SAVI]) mice. Recent discoveries revealed that STING also functions as a proton channel that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 5:S0092-8674(25)00096-0. doi: 10.1016/j.cell.2025.01.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Stimulator of interferon genes (STING) transmits signals downstream of the cytosolic DNA sensor cyclic guanosine monophosphate-AMP synthase (cGAS), leading to transcriptional upregulation of cytokines. However, components of the STING signaling pathway, such as IRF3 and IFNAR1, are not essential for autoinflammatory disease in STING gain-of-function (STING-associated vasculopathy with onset in infancy [SAVI]) mice. Recent discoveries revealed that STING also functions as a proton channel that deacidifies the Golgi apparatus. Because pH impacts Golgi enzyme activity, protein maturation, and trafficking, we hypothesized that STING proton channel activity influences multiple Golgi functions. Here, we show that STING-mediated proton efflux non-transcriptionally regulates Golgi trafficking of protein cargos. This process requires the Golgi-associated protein ArfGAP2, a cell-type-specific dual regulator of STING-mediated proton efflux and signaling. Deletion of ArfGAP2 in hematopoietic and endothelial cells markedly reduces STING-mediated cytokine and chemokine secretion, immune cell activation, and autoinflammatory pathology in SAVI mice. Thus, ArfGAP2 facilitates STING-mediated signaling and cytokine release in hematopoietic cells, significantly contributing to autoinflammatory disease pathogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39947179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39947179</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.027>10.1016/j.cell.2025.01.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39947179</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Subhajit Poddar</dc:creator>
<dc:creator>Samuel D Chauvin</dc:creator>
<dc:creator>Christopher H Archer</dc:creator>
<dc:creator>Wei Qian</dc:creator>
<dc:creator>Jean A Castillo-Badillo</dc:creator>
<dc:creator>Xin Yin</dc:creator>
<dc:creator>W Miguel Disbennett</dc:creator>
<dc:creator>Cathrine A Miner</dc:creator>
<dc:creator>Joe A Holley</dc:creator>
<dc:creator>Teresa V Naismith</dc:creator>
<dc:creator>W Alexander Stinson</dc:creator>
<dc:creator>Xiaochao Wei</dc:creator>
<dc:creator>Yue Ning</dc:creator>
<dc:creator>Jiayuan Fu</dc:creator>
<dc:creator>Trini A Ochoa</dc:creator>
<dc:creator>Nehalee Surve</dc:creator>
<dc:creator>Shivam A Zaver</dc:creator>
<dc:creator>Kimberly A Wodzanowski</dc:creator>
<dc:creator>Katherine R Balka</dc:creator>
<dc:creator>Rajan Venkatraman</dc:creator>
<dc:creator>Canyu Liu</dc:creator>
<dc:creator>Kelly Rome</dc:creator>
<dc:creator>Will Bailis</dc:creator>
<dc:creator>Yoko Shiba</dc:creator>
<dc:creator>Sara Cherry</dc:creator>
<dc:creator>Sunny Shin</dc:creator>
<dc:creator>Clay F Semenkovich</dc:creator>
<dc:creator>Dominic De Nardo</dc:creator>
<dc:creator>Sunnie Yoh</dc:creator>
<dc:creator>Elisha D O Roberson</dc:creator>
<dc:creator>Sumit K Chanda</dc:creator>
<dc:creator>David J Kast</dc:creator>
<dc:creator>Jonathan J Miner</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ArfGAP2 promotes STING proton channel activity, cytokine transit, and autoinflammation</dc:title>
<dc:identifier>pmid:39947179</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.027</dc:identifier>
</item>
<item>
<title>Fiber, Fatty Acids, and Blood Pressure: A Gut-Level Solution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39946444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 14;136(4):358-360. doi: 10.1161/CIRCRESAHA.125.326065. Epub 2025 Feb 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39946444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39946444</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326065>10.1161/CIRCRESAHA.125.326065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39946444</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Mohd Mabood Khan</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Fiber, Fatty Acids, and Blood Pressure: A Gut-Level Solution</dc:title>
<dc:identifier>pmid:39946444</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326065</dc:identifier>
</item>
<item>
<title>Mineral Stress and Vascular Aging: Decoding the Epigenetic Connection to Slow the Clock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39946443/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 14;136(4):400-402. doi: 10.1161/CIRCRESAHA.125.326064. Epub 2025 Feb 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39946443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39946443</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326064>10.1161/CIRCRESAHA.125.326064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39946443</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Qian Li</dc:creator>
<dc:creator>Lifang Ye</dc:creator>
<dc:creator>Jeffrey J Hsu</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mineral Stress and Vascular Aging: Decoding the Epigenetic Connection to Slow the Clock</dc:title>
<dc:identifier>pmid:39946443</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326064</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39946442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 14;136(4):355-357. doi: 10.1161/RES.0000000000000709. Epub 2025 Feb 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39946442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39946442</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000709>10.1161/RES.0000000000000709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39946442</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39946442</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000709</dc:identifier>
</item>
<item>
<title>Deciphering Platelets: Are They Cells or an Evolved Form of Extracellular Vesicles?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39946441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Platelets are abundant in blood, where they maintain the integrity of the vasculature. Megakaryocytes, the cells responsible for platelet genesis, produce membrane protrusions from which as many as 5000 anucleate platelets can be released into the bloodstream. Platelets lack genomic DNA but contain different molecules, such as RNA, as well as organelles transmitted from the parent megakaryocyte. There is no consensus in the scientific community on whether platelets are cells or not: for example,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 14;136(4):442-452. doi: 10.1161/CIRCRESAHA.124.324721. Epub 2025 Feb 13.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Platelets are abundant in blood, where they maintain the integrity of the vasculature. Megakaryocytes, the cells responsible for platelet genesis, produce membrane protrusions from which as many as 5000 anucleate platelets can be released into the bloodstream. Platelets lack genomic DNA but contain different molecules, such as RNA, as well as organelles transmitted from the parent megakaryocyte. There is no consensus in the scientific community on whether platelets are cells or not: for example, they are sometimes called cells, small cells, anucleated cells, cell fragments, or megakaryocyte fragments. Extracellular vesicles are particles delimited by a lipid bilayer that are released from cells but cannot replicate on their own. Like platelets, extracellular vesicles lack a nucleus and carry components from their donor cell. Herein, we will explore various viewpoints suggesting that platelets may be cells, albeit not conventional cells, or may be a previously unrecognized type of extracellular vesicle. Beyond a mere debate over terminology, this perspective seeks to help properly define and classify platelets, aiming for better integration into the concept of either cells or extracellular vesicles. This will foster a clearer understanding and drive advances in platelet research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39946441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39946441</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324721>10.1161/CIRCRESAHA.124.324721</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39946441</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Eric Boilard</dc:creator>
<dc:creator>Dylan Burger</dc:creator>
<dc:creator>Edit Buzas</dc:creator>
<dc:creator>Paolo Gresele</dc:creator>
<dc:creator>Kellie R Machlus</dc:creator>
<dc:creator>Nigel Mackman</dc:creator>
<dc:creator>Pia Siljander</dc:creator>
<dc:creator>Rienk Nieuwland</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Deciphering Platelets: Are They Cells or an Evolved Form of Extracellular Vesicles?</dc:title>
<dc:identifier>pmid:39946441</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324721</dc:identifier>
</item>
<item>
<title>Cardiovascular Disease in Anabolic Androgenic Steroid Users</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.071117. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Use of anabolic androgenic steroids (AASs) is associated with increased mortality, and case reports have suggested that some of these deaths are due to cardiovascular disease. However, the epidemiology of cardiovascular disease in AAS users is still relatively unexplored. This study aimed to measure the incidence of cardiovascular disease in male AAS users and to compare these rates with those of a cohort from the general population matched by age and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Men sanctioned in an antidoping program for AAS use in Danish fitness centers between 2006 and 2018 were included and matched for age and sex with 50 times as many controls from the general Danish population. The cohort was followed until June 30, 2023. Using the nationwide registries, we obtained information on admissions, prescriptions, educational length, and occupational status for both the AAS users and controls. This study investigated the incidence of acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft, venous thromboembolism, ischemic stroke, arrhythmia, cardiomyopathy, heart failure, and cardiac arrest during the follow-up period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During an average of 11 years of follow-up, AAS users (n=1189) demonstrated a significantly higher incidence of several cardiovascular events compared with controls (n=59 450). Correspondingly, AASs were associated with an increased risk of acute myocardial infarction (adjusted hazard ratio [aHR] 3.00 [95% CI, 1.67-5.39]), percutaneous coronary intervention or coronary artery bypass graft (aHR 2.95 [95% CI, 1.68-5.18]), venous thromboembolism (aHR 2.42 [95% CI, 1.54-3.80]), arrhythmias (aHR 2.26 [95% CI, 1.53-3.32]), cardiomyopathy (aHR 8.90 [95% CI, 4.99-15.88]), and heart failure (aHR 3.63 [95% CI, 2.01-6.55]). Due to the limited number of ischemic stroke and cardiac arrest cases among AAS users, these outcomes were not reportable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39945117</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071117>10.1161/CIRCULATIONAHA.124.071117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945117</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Josefine Windfeld-Mathiasen</dc:creator>
<dc:creator>Ida M Heerfordt</dc:creator>
<dc:creator>Kim Peder Dalhoff</dc:creator>
<dc:creator>Jon Trærup Andersen</dc:creator>
<dc:creator>Michael Asger Andersen</dc:creator>
<dc:creator>Karl Sebastian Johansson</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:creator>Flemming Javier Olsen</dc:creator>
<dc:creator>Henrik Horwitz</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Disease in Anabolic Androgenic Steroid Users</dc:title>
<dc:identifier>pmid:39945117</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071117</dc:identifier>
</item>
<item>
<title>Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIR.0000000000001300. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged. The coronary care unit gradually evolved from a focus on rapid resuscitation from ventricular arrhythmias in acute myocardial infarction into a comprehensive cardiac intensive care unit designed to care for the sickest patients with cardiovascular disease. Over the past decade, the cardiac intensive care unit has continued to transform with an aging population, increased clinical acuity, burgeoning cardiac and noncardiac comorbidities, technologic advances in cardiovascular interventions, and increased use of temporary mechanical circulatory support devices. Herein, we provide an update and contemporary expert perspective on the organizational structure, staffing, and care delivery in the cardiac intensive care unit; examine the challenges and opportunities present in the education and training of the next generation of physicians for critical care cardiology; and explore quality improvement initiatives and scientific investigation, including multicenter registry initiatives and randomized clinical trials, that may change clinical practice, care delivery, and the research landscape in this rapidly evolving discipline.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39945062</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001300>10.1161/CIR.0000000000001300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945062</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>Bram J Geller</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Cynthia Arslanian-Engoren</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:creator>Amanda R Vest</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Kidney in Cardiovascular Disease</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39945062</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001300</dc:identifier>
</item>
<item>
<title>Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A combination of myocardin and all-trans retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.070217. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although cell therapy has emerged as a promising approach to promote neovascularization, its effects are mostly limited to capillaries. To generate larger or stable vessels, layering of mural cells such as smooth muscle cells (SMCs) or pericytes is required. Recently, direct reprogramming approaches have been developed for generating SMCs. However, such reprogrammed SMCs lack genuine features of contractile SMCs, a native SMC phenotype; thus, their therapeutic and vessel-forming potential in vivo was not explored. Therefore, we aimed to directly reprogram human dermal fibroblasts toward contractile SMCs (rSMCs) and investigated their role for generating vascular mural cells in vivo and their therapeutic effects on ischemic disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied myocardin and all-<i>trans</i> retinoic acid with specific culture conditions to directly reprogram human dermal fibroblasts into rSMCs. We characterized their phenotype as contractile SMCs through quantitative reverse-transcriptase polymerase chain reaction, flow cytometry, and immunostaining. We then explored their contractility using a vasoconstrictor, carbachol, and through transmission electron microscope and bulk RNA sequencing. Next, we evaluated whether transplantation of rSMCs improves blood flow and induces vessel formation as mural cells in a mouse model of hind-limb ischemia with laser Doppler perfusion imaging and histological analysis. We also determined their paracrine effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our novel culture conditions using myocardin and all-<i>trans</i> retinoic acid efficiently reprogrammed human dermal fibroblasts into SMCs. These rSMCs displayed characteristics of contractile SMCs at the mRNA, protein, and cellular levels. Transplantation of rSMCs into ischemic mouse hind limbs enhanced blood flow recovery and vascular repair and improved limb salvage. Histological examination showed that vascular density was increased and the engrafted rSMCs were incorporated into the vascular wall as pericytes and vascular SMCs, thereby contributing to formation of stabler and larger microvessels. Quantitative reverse-transcriptase polymerase chain reaction analysis revealed that these transplanted rSMCs exerted pleiotropic effects, including angiogenic, arteriogenic, vessel-stabilizing, and tissue regenerative effects, on ischemic limbs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A combination of myocardin and all-<i>trans</i> retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39945059</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070217>10.1161/CIRCULATIONAHA.124.070217</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945059</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cholomi Jung</dc:creator>
<dc:creator>Ji Woong Han</dc:creator>
<dc:creator>Shin-Jeong Lee</dc:creator>
<dc:creator>Kyung Hee Kim</dc:creator>
<dc:creator>Jee Eun Oh</dc:creator>
<dc:creator>Seongho Bae</dc:creator>
<dc:creator>Sangho Lee</dc:creator>
<dc:creator>Young-Jae Nam</dc:creator>
<dc:creator>Sangsung Kim</dc:creator>
<dc:creator>Chaewon Dang</dc:creator>
<dc:creator>Jaehyun Kim</dc:creator>
<dc:creator>Nakhyung Chu</dc:creator>
<dc:creator>Eun Jig Lee</dc:creator>
<dc:creator>Young-Sup Yoon</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</dc:title>
<dc:identifier>pmid:39945059</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070217</dc:identifier>
</item>
<item>
<title>Therapeutic left-to-right shunting in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39943738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Heart failure with reduced or preserved ejection fraction are both associated with elevated left atrial pressure at rest due to fluid overload or during exercise, leading to pulmonary venous congestion. Even with available treatments, heart failure hospitalizations remain high, and improvements in quality-of-life scores and functional capacity are modest. Thus, there is growing interest in non-pharmacological methods to decompress the left atrium and improve heart failure symptoms and outcomes....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 13:ehaf120. doi: 10.1093/eurheartj/ehaf120. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure with reduced or preserved ejection fraction are both associated with elevated left atrial pressure at rest due to fluid overload or during exercise, leading to pulmonary venous congestion. Even with available treatments, heart failure hospitalizations remain high, and improvements in quality-of-life scores and functional capacity are modest. Thus, there is growing interest in non-pharmacological methods to decompress the left atrium and improve heart failure symptoms and outcomes. Left-to-right shunts have emerged as a potential therapeutic option to reduce left atrial hypertension, improve quality of life, and impact long-term outcomes. This nascent field carries both potential therapeutic promise as well as many unanswered questions. Recent data have questioned whether the effects of this therapy vary based on the left ventricular ejection fraction, pulmonary vascular resistance, and/or right ventricular structure and function. This review discusses the basis for left-to-right shunt therapies, synthesizes past and ongoing clinical trials, and offers future directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39943738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39943738</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf120>10.1093/eurheartj/ehaf120</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39943738</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Francesco Fioretti</dc:creator>
<dc:creator>Ajith P Nair</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Dean J Kereiakes</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Therapeutic left-to-right shunting in heart failure</dc:title>
<dc:identifier>pmid:39943738</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf120</dc:identifier>
</item>
<item>
<title>Clinical implications of perioperative and periprocedural myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 12. doi: 10.1038/s41569-025-01137-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39939396</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01137-y>10.1038/s41569-025-01137-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939396</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Konstantin A Krychtiuk</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Bernard J Gersh</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clinical implications of perioperative and periprocedural myocardial infarction</dc:title>
<dc:identifier>pmid:39939396</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01137-y</dc:identifier>
</item>
<item>
<title>Amara Yad Image: Cardiac Fibrous Skeleton-The Aortic Root, Tricuspid Valve, and the Membranous Septum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939045/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 18;85(6):655-656. doi: 10.1016/j.jacc.2024.12.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939045/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39939045</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.022>10.1016/j.jacc.2024.12.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939045</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: Cardiac Fibrous Skeleton-The Aortic Root, Tricuspid Valve, and the Membranous Septum</dc:title>
<dc:identifier>pmid:39939045</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.022</dc:identifier>
</item>
<item>
<title>Preprints: A Revolution in Cardiovascular Science</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 18;85(6):652-654. doi: 10.1016/j.jacc.2024.12.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39939044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.014>10.1016/j.jacc.2024.12.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939044</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Joshua D Wallach</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Preprints: A Revolution in Cardiovascular Science</dc:title>
<dc:identifier>pmid:39939044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.014</dc:identifier>
</item>
<item>
<title>Management of Coronary Stent Underexpansion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939043/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Coronary stent underexpansion is an important problem and limitation of percutaneous coronary intervention, adversely affecting both short- and long-term patient outcomes. Stent underexpansion occurs when a stent fails to expand adequately compared with the adjacent reference segment, resulting in inadequate luminal gain. Multiple studies suggest that stent underexpansion is associated with increased risks of in-stent restenosis, stent thrombosis, and myocardial infarction, resulting in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 18;85(6):625-644. doi: 10.1016/j.jacc.2024.12.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronary stent underexpansion is an important problem and limitation of percutaneous coronary intervention, adversely affecting both short- and long-term patient outcomes. Stent underexpansion occurs when a stent fails to expand adequately compared with the adjacent reference segment, resulting in inadequate luminal gain. Multiple studies suggest that stent underexpansion is associated with increased risks of in-stent restenosis, stent thrombosis, and myocardial infarction, resulting in recurrent symptoms, readmissions, repeat interventions, and increased mortality. Contributing factors for stent underexpansion include severe calcification, inadequate lesion preparation, suboptimal stent deployment, and preexisting in-stent restenosis. Calcific plaques, especially when present behind a previously implanted, underexpanded stent, pose a significant challenge for further stent optimization. These lesions are often resistant to high-pressure balloon dilatation and may require advanced techniques that carry increased risks of complications. Intravascular imaging modalities, such as intravascular ultrasound and optical coherence tomography, have emerged as essential tools in diagnosing and managing stent underexpansion. These techniques provide a more detailed evaluation of the vessel and previously implanted stent, enabling the clinician to understand the exact mechanism of stent failure, and assess plaque burden and morphology, which ultimately helps guide appropriate treatment strategies. Despite the clinical importance of stent underexpansion, there is currently no consensus on its optimal treatment, largely because of the absence of large prospective studies in this area. This comprehensive review aims to summarize the existing evidence, clinical experience, and treatment strategies for coronary stent underexpansion, with the goal of providing practical guidance to clinicians to help optimize percutaneous coronary intervention and patient outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939043/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39939043</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.009>10.1016/j.jacc.2024.12.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939043</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Primero Ng</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:creator>Farouc A Jaffer</dc:creator>
<dc:creator>Darshan Doshi</dc:creator>
<dc:creator>Kevin J Croce</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:creator>Jarrod D Frizzell</dc:creator>
<dc:creator>Emmanouil S Brilakis</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>William L Lombardi</dc:creator>
<dc:creator>Lorenzo Azzalini</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Coronary Stent Underexpansion</dc:title>
<dc:identifier>pmid:39939043</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.009</dc:identifier>
</item>
<item>
<title>Retraction of: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 13:ehaf081. doi: 10.1093/eurheartj/ehaf081. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39938556</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf081>10.1093/eurheartj/ehaf081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938556</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Retraction of: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</dc:title>
<dc:identifier>pmid:39938556</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf081</dc:identifier>
</item>
<item>
<title>Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Huntington's disease (HD) modifiers include mismatch-repair (MMR) genes, but their connections to neuronal pathogenesis remain unclear. Here, we genetically tested 9 HD genome-wide association study (GWAS)/MMR genes in mutant Huntingtin (mHtt) mice with 140 inherited CAG repeats (Q140). Knockout (KO) of genes encoding a distinct MMR complex either strongly (Msh3 and Pms1) or moderately (Msh2 and Mlh1) rescues phenotypes with early onset in striatal medium-spiny neurons (MSNs) and late onset in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 8:S0092-8674(25)00100-X. doi: 10.1016/j.cell.2025.01.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Huntington's disease (HD) modifiers include mismatch-repair (MMR) genes, but their connections to neuronal pathogenesis remain unclear. Here, we genetically tested 9 HD genome-wide association study (GWAS)/MMR genes in mutant Huntingtin (mHtt) mice with 140 inherited CAG repeats (Q140). Knockout (KO) of genes encoding a distinct MMR complex either strongly (Msh3 and Pms1) or moderately (Msh2 and Mlh1) rescues phenotypes with early onset in striatal medium-spiny neurons (MSNs) and late onset in the cortical neurons: somatic CAG-repeat expansion, transcriptionopathy, and mHtt aggregation. Msh3 deficiency ameliorates open-chromatin dysregulation in Q140 neurons. Mechanistically, the fast linear rate of mHtt modal-CAG-repeat expansion in MSNs (8.8 repeats/month) is drastically reduced or stopped by MMR mutants. Msh3 or Pms1 deficiency prevents mHtt aggregation by keeping somatic MSN CAG length below 150. Importantly, Msh3 deficiency corrects synaptic, astrocytic, and locomotor defects in HD mice. Thus, Msh3 and Pms1 drive fast somatic mHtt CAG-expansion rates in HD-vulnerable neurons to elicit repeat-length/threshold-dependent, selective, and progressive pathogenesis in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39938516</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.031>10.1016/j.cell.2025.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938516</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nan Wang</dc:creator>
<dc:creator>Shasha Zhang</dc:creator>
<dc:creator>Peter Langfelder</dc:creator>
<dc:creator>Lalini Ramanathan</dc:creator>
<dc:creator>Fuying Gao</dc:creator>
<dc:creator>Mary Plascencia</dc:creator>
<dc:creator>Raymond Vaca</dc:creator>
<dc:creator>Xiaofeng Gu</dc:creator>
<dc:creator>Linna Deng</dc:creator>
<dc:creator>Leonardo E Dionisio</dc:creator>
<dc:creator>Ha Vu</dc:creator>
<dc:creator>Emily Maciejewski</dc:creator>
<dc:creator>Jason Ernst</dc:creator>
<dc:creator>Brinda C Prasad</dc:creator>
<dc:creator>Thomas F Vogt</dc:creator>
<dc:creator>Steve Horvath</dc:creator>
<dc:creator>Jeffrey S Aaronson</dc:creator>
<dc:creator>Jim Rosinski</dc:creator>
<dc:creator>X William Yang</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice</dc:title>
<dc:identifier>pmid:39938516</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.031</dc:identifier>
</item>
<item>
<title>Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal adenocarcinoma [PDAC]) and advanced-stage disease. Here, we demonstrate that pro-thrombotic small extracellular vesicles (sEVs) are secreted by C-X-C motif chemokine 13 (CXCL13)-reprogrammed interstitial macrophages in the non-metastatic lung microenvironment of multiple cancers, a niche that we define...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 10:S0092-8674(25)00094-7. doi: 10.1016/j.cell.2025.01.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal adenocarcinoma [PDAC]) and advanced-stage disease. Here, we demonstrate that pro-thrombotic small extracellular vesicles (sEVs) are secreted by C-X-C motif chemokine 13 (CXCL13)-reprogrammed interstitial macrophages in the non-metastatic lung microenvironment of multiple cancers, a niche that we define as the pro-thrombotic niche (PTN). These sEVs package clustered integrin β<sub>2</sub> that dimerizes with integrin α<sub>X</sub> and interacts with platelet-bound glycoprotein (GP)Ib to induce platelet aggregation. Blocking integrin β<sub>2</sub> decreases both sEV-induced thrombosis and lung metastasis. Importantly, sEV-β<sub>2</sub> levels are elevated in the plasma of PDAC patients prior to thrombotic events compared with patients with no history of thrombosis. We show that lung PTN establishment is a systemic consequence of cancer progression and identify sEV-β<sub>2</sub> as a prognostic biomarker of thrombosis risk as well as a target to prevent thrombosis and metastasis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39938515</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.025>10.1016/j.cell.2025.01.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938515</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Serena Lucotti</dc:creator>
<dc:creator>Yusuke Ogitani</dc:creator>
<dc:creator>Candia M Kenific</dc:creator>
<dc:creator>Jacob Geri</dc:creator>
<dc:creator>Young Hun Kim</dc:creator>
<dc:creator>Jinghua Gu</dc:creator>
<dc:creator>Uthra Balaji</dc:creator>
<dc:creator>Linda Bojmar</dc:creator>
<dc:creator>Lee Shaashua</dc:creator>
<dc:creator>Yi Song</dc:creator>
<dc:creator>Michele Cioffi</dc:creator>
<dc:creator>Pernille Lauritzen</dc:creator>
<dc:creator>Oveen M Joseph</dc:creator>
<dc:creator>Tetsuhiko Asao</dc:creator>
<dc:creator>Paul M Grandgenett</dc:creator>
<dc:creator>Michael A Hollingsworth</dc:creator>
<dc:creator>Christopher Peralta</dc:creator>
<dc:creator>Alexandra E Pagano</dc:creator>
<dc:creator>Henrik Molina</dc:creator>
<dc:creator>Harry B Lengel</dc:creator>
<dc:creator>Elizabeth G Dunne</dc:creator>
<dc:creator>Xiaohong Jing</dc:creator>
<dc:creator>Madeleine Schmitter</dc:creator>
<dc:creator>Lucia Borriello</dc:creator>
<dc:creator>Thomas Miller</dc:creator>
<dc:creator>Haiying Zhang</dc:creator>
<dc:creator>Yevgeniy Romin</dc:creator>
<dc:creator>Katia Manova</dc:creator>
<dc:creator>Doru Paul</dc:creator>
<dc:creator>H Lawrence Remmel</dc:creator>
<dc:creator>Eileen M O'Reilly</dc:creator>
<dc:creator>William R Jarnagin</dc:creator>
<dc:creator>David Kelsen</dc:creator>
<dc:creator>Sharon M Castellino</dc:creator>
<dc:creator>Lisa Giulino-Roth</dc:creator>
<dc:creator>David R Jones</dc:creator>
<dc:creator>John S Condeelis</dc:creator>
<dc:creator>Virginia Pascual</dc:creator>
<dc:creator>James B Bussel</dc:creator>
<dc:creator>Nancy Boudreau</dc:creator>
<dc:creator>Irina Matei</dc:creator>
<dc:creator>David Entenberg</dc:creator>
<dc:creator>Jacqueline F Bromberg</dc:creator>
<dc:creator>Diane M Simeone</dc:creator>
<dc:creator>David Lyden</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2</dc:title>
<dc:identifier>pmid:39938515</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.025</dc:identifier>
</item>
<item>
<title>Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>Although subsets with immunosuppressive properties exist, neutrophils are typically known for their pro-inflammatory role and pathogen clearance capabilities. Here, we reveal that neutrophils can paradoxically aid in resolving inflammation by actively producing anti-inflammatory extracellular vesicles. These large aging-neutrophil-derived vesicles (LAND-Vs) do not fit into classical vesicle categorizations due to their specific size, structure, or biogenesis pathway. They are protected from...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 3:S0092-8674(25)00050-9. doi: 10.1016/j.cell.2025.01.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although subsets with immunosuppressive properties exist, neutrophils are typically known for their pro-inflammatory role and pathogen clearance capabilities. Here, we reveal that neutrophils can paradoxically aid in resolving inflammation by actively producing anti-inflammatory extracellular vesicles. These large aging-neutrophil-derived vesicles (LAND-Vs) do not fit into classical vesicle categorizations due to their specific size, structure, or biogenesis pathway. They are protected from efferocytotic clearance by phagocytes due to surface "do not eat me" signals and accumulate in the resolution phase of inflammation. CD55 on LAND-Vs exerts a robust, sustained anti-inflammatory effect by inhibiting complement 3 convertase, thereby reducing neutrophil recruitment and tissue damage. CD55<sup>+</sup> LAND-Vs originate in ordered lipid raft domains, where CD55 accumulates asymmetrically during neutrophil aging, and are subsequently formed through RhoA-dependent budding. Collectively, LAND-V emerges as a pivotal physiological immunomodulator and showcases functions that transcend the limited lifespan of neutrophils, offering a therapeutic target for inflammatory and infectious diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39938514</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.021>10.1016/j.cell.2025.01.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938514</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Alan Y Hsu</dc:creator>
<dc:creator>Qingxiang Huang</dc:creator>
<dc:creator>Xiong Pi</dc:creator>
<dc:creator>Jianing Fu</dc:creator>
<dc:creator>Krishnan Raghunathan</dc:creator>
<dc:creator>Laxman Ghimire</dc:creator>
<dc:creator>Arumugam Balasubramanian</dc:creator>
<dc:creator>Xuemei Xie</dc:creator>
<dc:creator>Hongbo Yu</dc:creator>
<dc:creator>Fabien Loison</dc:creator>
<dc:creator>Viraga Haridas</dc:creator>
<dc:creator>Jiali Zha</dc:creator>
<dc:creator>Fei Liu</dc:creator>
<dc:creator>Shin-Young Park</dc:creator>
<dc:creator>Kamal Bagale</dc:creator>
<dc:creator>Qian Ren</dc:creator>
<dc:creator>Yuping Fan</dc:creator>
<dc:creator>Yi Zheng</dc:creator>
<dc:creator>Jose A Cancelas</dc:creator>
<dc:creator>Li Chai</dc:creator>
<dc:creator>Sean R Stowell</dc:creator>
<dc:creator>Kanchao Chen</dc:creator>
<dc:creator>Rong Xu</dc:creator>
<dc:creator>Xiaoxue Wang</dc:creator>
<dc:creator>Yuanfu Xu</dc:creator>
<dc:creator>Lianghui Zhang</dc:creator>
<dc:creator>Tao Cheng</dc:creator>
<dc:creator>Fengxia Ma</dc:creator>
<dc:creator>Jay R Thiagarajah</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Sizhou Feng</dc:creator>
<dc:creator>Hongbo R Luo</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution</dc:title>
<dc:identifier>pmid:39938514</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.021</dc:identifier>
</item>
<item>
<title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12:e245537. doi: 10.1001/jamacardio.2024.5537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39937520</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11822591/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">PMC11822591</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5537>10.1001/jamacardio.2024.5537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937520</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Adeena Jamil</dc:creator>
<dc:creator>Muteia Shakoor</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>J Michael DiMaio</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</dc:title>
<dc:identifier>pmid:39937520</dc:identifier>
<dc:identifier>pmc:PMC11822591</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5537</dc:identifier>
</item>
<item>
<title>Intensive Blood Pressure Control in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250214051130&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5447. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250214051130&v=2.18.0.post9+e462414">39937510</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5447>10.1001/jamacardio.2024.5447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937510</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuxian Huang</dc:creator>
<dc:creator>Xiangmin Tan</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Intensive Blood Pressure Control in Older Adults</dc:title>
<dc:identifier>pmid:39937510</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5447</dc:identifier>
</item>





























</channel>
</rss>